Martínek Petr, Grossmann Petr, Hes Ondřej, Bouda Jiří, Eret Viktor, Frizzell Norma, Gill Anthony J, Ondič Ondrej
Šikl's Department of Pathology, University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague, alej Svobody 80, 304 60, Pilsen, Czech Republic.
Virchows Arch. 2015 Aug;467(2):185-91. doi: 10.1007/s00428-015-1783-y. Epub 2015 May 19.
We have studied the viability of targeted molecular screening for the identification of female patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. Affected patients harbor a germ-line heterozygous mutation of the fumarate hydratase (FH) gene. Clinically, some patients present with aggressive renal cell carcinoma. Concerning women, in almost all cases, this is preceded by symptomatic uterine leiomyoma. We aimed to identify women operated on for symptomatic leiomyoma by the age of 30. Archived paraffin-embedded leiomyoma tissue was tested for the FH gene mutation in 14 cases. Two patients with multiple leiomyomas and with the confirmed germ-line mutations c.1433_1434dupAAA, p.(Lys477dup) and c.953A>T, p.(His318Leu) were identified and enrolled in a surveillance program. Statistically significant correlation between the presence of multiple uterine leiomyomas (more than seven in our experience) and the FH gene mutation was found. The immunohistochemical expression pattern, of simultaneous FH absence and S-(2-succino)cysteine (2SC) positivity, correlated with the results of the molecular genetic study in only one case. The histomorphologically simultaneous detection of enlarged nucleoli with a clear halo of leiomyocyte nuclei, their fibrillary cytoplasm, the presence of eosinophilic globules, and staghorn vessels proved to be only a partially sensitive indicator of HLRCC-associated leiomyoma and fully correlated with immunohistochemistry and molecular genetic study only in one case. Molecular genetic testing is presently the only reliable diagnostic tool able to identify HLRCC patients. The sensitivity and specificity of the presence of multiple leiomyomas in women with the FH gene mutation who are younger than 30 years old should be confirmed in larger scale studies. The applied targeted molecular screening protocol proved to be effective, resulting in identification of two positive patients out of fourteen tested individuals.
我们研究了靶向分子筛查用于识别遗传性平滑肌瘤病和肾细胞癌(HLRCC)综合征女性患者的可行性。受影响的患者携带延胡索酸水合酶(FH)基因的种系杂合突变。临床上,一些患者表现为侵袭性肾细胞癌。对于女性而言,几乎在所有情况下,在此之前都有症状性子宫平滑肌瘤。我们的目标是识别出30岁前因症状性平滑肌瘤接受手术的女性。对14例存档的石蜡包埋平滑肌瘤组织进行了FH基因突变检测。鉴定出两名患有多发性平滑肌瘤且携带已确认种系突变c.1433_1434dupAAA、p.(Lys477dup)和c.953A>T、p.(His318Leu)的患者,并将其纳入监测计划。发现多发性子宫平滑肌瘤(根据我们的经验,超过七个)的存在与FH基因突变之间存在统计学上的显著相关性。仅在一例中,FH同时缺失和S-(2-琥珀酰)半胱氨酸(2SC)阳性的免疫组化表达模式与分子遗传学研究结果相关。组织形态学上同时检测到平滑肌瘤细胞核仁增大且有清晰晕圈、其纤维状细胞质、嗜酸性小球的存在以及鹿角状血管,结果证明这只是HLRCC相关平滑肌瘤的部分敏感指标,仅在一例中与免疫组化和分子遗传学研究完全相关。分子遗传学检测目前是能够识别HLRCC患者的唯一可靠诊断工具。FH基因突变且年龄小于30岁的女性中多发性平滑肌瘤存在的敏感性和特异性应在更大规模的研究中得到证实。所应用的靶向分子筛查方案被证明是有效的,在14名检测个体中识别出两名阳性患者。